Clinical Trials Info:
734.936.7519

Eczema (Atopic Dermatitis) Clinical Studies

Tissue Acquisition of Skin and Blood from Patients with Atopic Dermatitis and Hidradenitis Suppurativa

Enrollment status: Open

The purpose of this study is to collect skin, blood, and urine samples from patients with eczema, also called atopic dermatitis, which is an itchy, red, inflammation of the skin, or hidradentis suppurativa (a chronic skin condition featuring painful lumps or boils and eventually open wounds in places such as the armpits or groin).

Study Coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 700

An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients > 6 months to < 18 years of age with atopic dermatitis

Enrollment status: Contact us for status

This study is being conducted to determine whether dupilumab is safe in children suffering from AD and to understand whether dupilumab has beneficial effects on the disease in children suffering from AD.  This drug is not yet approved by government agencies, such as the US Food and Drug Administration (FDA) for the treatment of AD in children. Dupilumab is, however, approved by the FDA for the treatment of AD in adults. Dupilumab is a type of drug called a “monoclonal antibody”.  An antibody is a special kind of protein that the immune system normally makes to fight bacteria and viruses.  Scientists can now make antibodies in the laboratory and produce them for the treatment of many different diseases. Dupilumab was designed to target specific molecules thought to play a role in atopic dermatitis.

Study Coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 718

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescents and Adult Subjects with Moderate to Severe Atopic Dermatitis

Enrollment status: Contact us for status

The purpose of this study is to compare the effectiveness and safety of upadacitinib (ABT-494) to placebo (pill without any active substance that looks like upadacitinib) for adolescents (12-17 years of age) and adults (18-75 years of age) with moderate to severe atopic dermatitis (AD)

Study Coordinator: Aaron Rankin, (734) 936-7519 or dermtrials@med.umich.edu
Please reference Derm #: 732